KDMN Kadmon Holdings, Inc.

2.45
-0.02  -1%
Previous Close 2.47
Open 2.51
Price To book 0.00
Market Cap 127.02M
Shares 51,846,000
Volume 95,869
Short Ratio 6.01
Av. Daily Volume 208,498

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 3Q 2017.
Tesevatinib
Autosomal dominant Polycystic Kidney Disease (ADPKD)
Phase 2 initiated September 2016. Data due 3Q 2017.
KD025
Chronic graft-versus-host disease (cGVHD)
Phase 2 data due 4Q 2017.
KD025
Idiopathic pulmonary fibrosis (IPF)
Phase 2 first patient dosed September 2016. Data due 4Q 2017.
KD025
Moderate to severe chronic plaque psoriasis
Phase 2 initiated August 2016. Enrollment ongoing as of May 15, 2017.
Tesevatinib
Recurrent glioblastoma - cancer
Phase 2 data on the first 13 patients to be presented at the IASLC 17th World Conference on Lung Cancer December 6 2016.
Tesevatinib
EGFR-mutant non-small cell lung cancer (NSCLC) that has metastasized to the brain

Latest News

  1. Robbins Arroyo LLP Is Investigating the Officers and Directors of Kadmon Holdings, Inc. (KDMN) on Behalf of Shareholders
  2. Scott+Scott, Attorneys at Law, LLP Announces Investigation of Kadmon Holdings Inc. (KDMN)
  3. Kadmon Provides Business Update and Reports First Quarter 2017 Financial Results
  4. Kadmon to Present Clinical and Preclinical Data Highlighting the Role of ROCK2 Signaling in Immune System Function at AAI Annual Meeting
  5. Kadmon Announces Publication of Clinical Data Showing KD025 Improved Clinical Scores in Psoriasis Patients
  6. Kadmon Submits Second Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA
  7. Kadmon Announces Amendment to Credit Agreement and Related Warrants
  8. ETFs with exposure to Kadmon Holdings, Inc. : March 30, 2017
  9. Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis
  10. Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017
  11. Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results
  12. Kadmon Announces Approximately $23 Million Equity Financing
  13. Hedge Funds Are Buying Kadmon Holdings LLC (KDMN)
  14. Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases
  15. Kadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA
  16. Kadmon to Present at the 28th Annual Piper Jaffray Healthcare Conference
  17. Kadmon to Present at the Jefferies 2016 London Healthcare Conference
  18. Kadmon Provides Business Update and Reports Third Quarter 2016 Financial Results
  19. Kadmon to Present at the 15th Annual BIO Investor Forum
  20. Allergan's Vitae Buy Could Spark More Interest in Kadmon